Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Genetic variation in NDFIP1 modifies the metabolic patterns in immune cells of multiple sclerosis patients

  • López-Cotarelo, Pilar
  • González-Jiménez, Adela
  • Agudo-Jiménez, Teresa
  • Abarca-Zabalía, Judith
  • Aladro, Yolanda|||0000-0001-9459-5452
  • Pilo, Belén
  • Comabella López, Manuel|||0000-0002-2373-6657
  • Espino-Paisan, Laura
  • Urcelay, Elena|||0000-0001-8470-8396
One of the 233 polymorphisms associated with multiple sclerosis (MS) susceptibility lies within the NDFIP1 gene, and it was previously identified as eQTL in healthy controls. NDFIP1 shows interesting immune functions and is involved in the development of the central nervous system. We aimed at studying the NDFIP1 variant on activation and metabolism of immune cells. NDFIP1 mRNA and protein expression were assessed in PBMCs by qPCR and western blot in 87 MS patients and 84 healthy controls genotyped for rs4912622. Immune activation after PHA stimulation was evaluated by CD69 upregulation, and metabolic function of both basal and PHA-activated lymphocytes was studied by Seahorse Xfp-Analyzer. In minor-allele homozygous controls but not in patients, we found higher NDFIP1 expression, significantly reduced protein levels, and CD69 upregulation in B- and T-cells. PBMCs from minor-allele homozygous controls showed significantly higher basal mitochondrial respiration and ATP production compared to major-allele carriers, while minor-allele homozygous patients showed significantly lower metabolic activity than carriers of the major allele. In conclusion, we describe associations in minor-allele homozygous controls with lower levels of NDFIP1 protein, CD69 upregulation, and raised mitochondrial activity, which are not replicated in MS patients, suggesting a NDFIP1 differential effect in health and disease.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Exome sequencing study in patients with multiple sclerosis reveals variants associated with disease course

  • Gil Varea, Elia|||0000-0001-5144-4144
  • Urcelay, Elena|||0000-0001-8470-8396
  • Vilariño-Güell, Carles|||0000-0002-5612-5940
  • Costa, Carme|||0000-0001-9577-3839
  • Midaglia, Luciana|||0000-0001-7981-2228
  • Matesanz, Fuencisla|||0000-0002-9429-1819
  • Rodríguez Antigüedad, Alfredo|||0000-0001-5975-725X
  • Oksenberg, Jorge
  • Espino-Paisan, Laura
  • Dessa Sadovnick, A.
  • Saiz, Albert|||0000-0002-5793-8791
  • Villar, Luisa M.|||0000-0002-9067-3668
  • García Merino, Juan Antonio
  • Ramió-Torrentà, Lluís|||0000-0002-6999-1004
  • Triviño, Juan Carlos
  • Quintana, Ester|||0000-0001-8885-1931
  • Robles, René
  • Sánchez López, Antonio José|||0000-0001-7168-6175
  • Arroyo, Rafael
  • Alvarez-Cermeño, José C.|||0000-0002-1345-2837
  • Vidal-Jordana, Angela|||0000-0002-7270-5507
  • Malhotra, Sunny|||0000-0003-1112-7739
  • Fissolo, Nicolás|||0000-0002-7701-9346
  • Montalban, Xavier|||0000-0002-0098-9918
  • Comabella López, Manuel|||0000-0002-2373-6657
It remains unclear whether disease course in multiple sclerosis (MS) is influenced by genetic polymorphisms. Here, we aimed to identify genetic variants associated with benign and aggressive disease courses in MS patients. MS patients were classified into benign and aggressive phenotypes according to clinical criteria. We performed exome sequencing in a discovery cohort, which included 20 MS patients, 10 with benign and 10 with aggressive disease course, and genotyping in 2 independent validation cohorts. The first validation cohort encompassed 194 MS patients, 107 with benign and 87 with aggressive phenotypes. The second validation cohort comprised 257 patients, of whom 224 patients had benign phenotypes and 33 aggressive disease courses. Brain immunohistochemistries were performed using disease course associated genes antibodies. By means of single-nucleotide polymorphism (SNP) detection and comparison of allele frequencies between patients with benign and aggressive phenotypes, a total of 16 SNPs were selected for validation from the exome sequencing data in the discovery cohort. Meta-analysis of genotyping results in two validation cohorts revealed two polymorphisms, rs28469012 and rs10894768, significantly associated with disease course. SNP rs28469012 is located in CPXM2 (carboxypeptidase X, M14 family, member 2) and was associated with aggressive disease course (uncorrected p value < 0.05). SNP rs10894768, which is positioned in IGSF9B (immunoglobulin superfamily member 9B) was associated with benign phenotype (uncorrected p value < 0.05). In addition, a trend for association with benign phenotype was observed for a third SNP, rs10423927, in NLRP9 (NLR family pyrin domain containing 9). Brain immunohistochemistries in chronic active lesions from MS patients revealed expression of IGSF9B in astrocytes and macrophages/microglial cells, and expression of CPXM2 and NLRP9 restricted to brain macrophages/microglia. Genetic variants located in CPXM2, IGSF9B, and NLRP9 have the potential to modulate disease course in MS patients and may be used as disease activity biomarkers to identify patients with divergent disease courses. Altogether, the reported results from this study support the influence of genetic factors in MS disease course and may help to better understand the complex molecular mechanisms underlying disease pathogenesis. The online version of this article (10.1186/s12974-018-1307-1) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A New Risk Variant for Multiple Sclerosis at 11q23.3 Locus Is Associated with Expansion of CXCR5+ Circulating Regulatory T Cells

  • Gil Varea, Elia|||0000-0001-5144-4144
  • Fedetz, Maria
  • Eixarch, Herena|||0000-0001-7525-9533
  • Spataro, Nino|||0000-0002-2127-2238
  • Villar, Luisa M.|||0000-0002-9067-3668
  • Urcelay, Elena|||0000-0001-8470-8396
  • Saiz, Albert|||0000-0002-5793-8791
  • Fernández Fernández, Óscar|||0000-0003-3696-789X
  • Leyva, Laura|||0000-0003-0620-9625
  • Ramió-Torrentà, Lluís|||0000-0002-6999-1004
  • Vandenbroeck, Koen|||0000-0002-6967-6485
  • Otaegui, David|||0000-0002-6625-5976
  • Castillo-Triviño, Tamara|||0000-0002-9249-3185
  • Izquierdo, Guillermo|||0000-0002-6340-5609
  • Malhotra, Sunny|||0000-0003-1112-7739
  • Bosch, Elena|||0000-0003-2848-103X
  • Navarro, Arcadi|||0000-0003-2162-8246
  • Alcina, Antonio|||0000-0001-7294-0948
  • Montalban, Xavier|||0000-0002-0098-9918
  • Matesanz, Fuencisla|||0000-0002-9429-1819
  • Comabella López, Manuel|||0000-0002-2373-6657
Genome-wide association studies and meta-analysis have contributed to the identification of more than 200 loci associated with multiple sclerosis (MS). However, a proportion of MS heritability remains unknown. We aimed to uncover new genetic variants associated with MS and determine their functional effects. For this, we resequenced the exons and regulatory sequences of 14 MS risk genes in a cohort of MS patients and healthy individuals (n = 1070) and attempted to validate a selection of signals through genotyping in an independent cohort (n = 5138). We identified three new MS-associated variants at C-X-C motif chemokine receptor 5 (CXCR5), Ts translation elongation factor, mitochondrial (TSFM) and cytochrome P450 family 24 subfamily A member 1 (CYP24A1). Rs10892307 resulted in a new signal at the CXCR5 region that explains one of the associations with MS within the locus. This polymorphism and three others in high linkage disequilibrium mapped within regulatory regions. Of them, rs11602393 showed allele-dependent enhancer activity in the forward orientation as determined by luciferase reporter assays. Immunophenotyping using peripheral blood mononuclear cells from MS patients associated the minor allele of rs10892307 with increased percentage of regulatory T cells expressing CXCR5. This work reports a new signal for the CXCR5 MS risk locus and points to rs11602393 as the causal variant. The expansion of CXCR5+ circulating regulatory T cells induced by this variant could cause its MS association.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A Polymorphism Within the MBP Gene Is Associated With a Higher Relapse Number in Male Patients of Multiple Sclerosis

  • Espino-Paisan, Laura
  • Agudo-Jiménez, Teresa
  • Rosales-Martínez, Isabel
  • López-Cotarelo, Pilar
  • García-Martínez, María Ángel
  • Domínguez-Mozo, María Inmaculada
  • Pérez-Pérez, Silvia
  • Dieli-Crimi, Romina|||0000-0003-3413-5133
  • Comabella López, Manuel|||0000-0002-2373-6657
  • Urcelay, Elena|||0000-0001-8470-8396
  • Alvarez-Lafuente, Roberto|||0000-0002-3132-1486
Myelin basic protein (MBP) is thought to be one of the key autoantigens in multiple sclerosis (MS) development. A recent study described the association of the single nucleotide polymorphism (SNP) rs12959006, within the MBP gene, with a higher risk of relapse and worse prognosis. We aim at studying potential associations of this SNP to MS in an independent population. Clinical data of the first 5 years of the disease were collected retrospectively from 291 MS confirmed patients. MBP polymorphism rs12959006 was genotyped in all patients. Associations with EDSS, number of relapses and serology for Herpesvirus 6 (HHV-6) and Epstein Barr (EBV) viruses were studied. Lymphocyte activation measured by CD69 expression was also analyzed according to sex and rs12959006 genotype. The rs12959006 polymorphism contributed significantly to a higher number of relapses at 5 years after onset only in male patients (rs12959006 ∗ TT β = 0.74 [0.36-1.09]; p = 7 × 10 -5). Titers of anti-HHV6 IgG antibodies showed also a mild association with relapses, both in male and female patients (β = 0.01 [0.01-0.02]; p = 3.7 × 10 -8). Both the genetic variation in MBP and HHV-6 infection aid in predicting a higher number of relapses during the first years of MS. The association described in MBP rs12959006 ∗ T is exclusive to male patients.